PGE synthase CRISPR Activation Plasmid (h): sc-402085-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PGE synthase CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- PGE synthase CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by PGE synthase CRISPR Activation Plasmid (h) and PGE synthase CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PTGES transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PGE synthase Antibody (A-3): sc-166308
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PGE synthase CRISPR Activation Plasmid (h) | sc-402085-ACT | 20 µg | $397.00 | |||
PGE synthase CRISPR Activation Plasmid (h2) | sc-402085-ACT-2 | 20 µg | $397.00 |
PTGES encodes microsomal prostaglandin E synthase-1 (mPGES-1), an inducible terminal enzyme in the arachidonic acid cascade that converts COX-derived PGH2 into prostaglandin E2 (PGE2). This activity links inflammatory cues to bioactive lipid mediator production and supports modulation of cytokine signaling, vascular tone, pain sensitization, and immune cell function. PTGES is regulated downstream of NF-κB and MAPK pathways and functions alongside PTGS1/2 and PLA2 enzymes to shape eicosanoid output. Altered PTGES/PGE2 signaling has been associated with chronic inflammatory states and tumor-associated microenvironment programs, making it a common target for mechanistic studies of inflammation-linked biology.
PGE synthase CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PTGES expression without altering the underlying DNA sequence.
PGE synthase CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PTGES locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PTGES transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous PGE synthase expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PTGES locus and enabling the study of PGE synthase-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of PGE synthase pathway restoration in tumor cells with silenced or reduced PTGES expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.